Cellosaurus OAW28 (CVCL_1614)

Cell line name OAW28
Synonyms OAW-28; OAW 28
Accession CVCL_1614
Resource Identification Initiative To cite this cell line use: OAW28 (RRID:CVCL_1614)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: OCCP ovarian cancer cell line panel.
Doubling time: 37 hours (PubMed=2653399); ~60 hours, at 20th passage (PubMed=8795574).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: OWA28; In Cosmic 1707570.
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_4993 (41M)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; ECACC; PubMed=25230021; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11
D13S31711
D16S53913
D18S5112,14
D19S43313
D21S1129
D2S133820,23
D3S135814,18
D5S81812
D7S82011
D8S117911,15
FGA21,24
Penta D9
Penta E7
TH019
TPOX8
vWA17,19
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=2653399; DOI=10.1038/bjc.1989.108
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Br. J. Cancer 59:527-534(1989)

PubMed=8795574; DOI=10.1038/bjc.1996.428
Wilson A.P., Dent M., Pejovic T., Hubbold L., Radford H.
Characterisation of seven human ovarian tumour cell lines.
Br. J. Cancer 74:722-727(1996)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ECACC; 85101601
Cell line databases/resources CLDB; cl3756
CCLE; OAW28_OVARY
Cosmic-CLP; 946360
GDSC; 946360
LINCS_LDP; LCL-1698
Ontologies CLO; CLO_0008228
EFO; EFO_0006704
Biological sample resources BioSample; SAMN03472477
Chemistry resources ChEMBL-Cells; CHEMBL3308479
ChEMBL-Targets; CHEMBL1075553
Gene expression databases GEO; GSM659383
GEO; GSM827435
GEO; GSM887464
GEO; GSM888544
GEO; GSM1291143
GEO; GSM1374778
GEO; GSM1670292
Polymorphism and mutation databases Cosmic; 946360
Cosmic; 1707570